Drug intelligence / Profile preview

ATB-223

Development stage: Unknown
Lead developer: AltiBio

Overview

ATB-223 is a discontinued therapeutic candidate that was developed by AltiBio, Inc. for the treatment of undisclosed rare diseases. The drug was advanced through preclinical trials in the United States, and as of September 2018, the company was planning to initiate Phase II clinical trials. However, specific details regarding its active ingredient, biological target, and modality were never publicly disclosed. AltiBio has since deprioritized ATB-223 in favor of other pipeline candidates such as ATB226 and ATB227, and the drug is no longer listed on the company's active development roster.

Beyond the preview

Go deeper on ATB-223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATB-223.

Explore the full profile